Immunome (IMNM) EBIAT (2023 - 2025)
Immunome (IMNM) has disclosed EBIAT for 3 consecutive years, with -$69.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 12.9% year-over-year to -$69.9 million, compared with a TTM value of -$212.4 million through Dec 2025, up 27.5%, and an annual FY2025 reading of -$212.4 million, up 27.5% over the prior year.
- EBIAT was -$69.9 million for Q4 2025 at Immunome, down from -$57.5 million in the prior quarter.
- Across five years, EBIAT topped out at -$4.3 million in Q1 2023 and bottomed at -$129.5 million in Q1 2024.
- Average EBIAT over 3 years is -$51.0 million, with a median of -$45.2 million recorded in 2024.
- The sharpest move saw EBIAT crashed 2932.6% in 2024, then surged 67.84% in 2025.
- Year by year, EBIAT stood at -$92.6 million in 2023, then increased by 13.37% to -$80.2 million in 2024, then increased by 12.9% to -$69.9 million in 2025.
- Business Quant data shows EBIAT for IMNM at -$69.9 million in Q4 2025, -$57.5 million in Q3 2025, and -$43.4 million in Q2 2025.